Table 5.
Possible reason of nonresponse to rescue therapy.
| Patient | GT | F | Primary therapy | Out come | Secondary therapy | ETR | Months between therapies | RAS | Comments |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 4 | OBV/PTV/r +DSV+RBV 12 weeks |
REL | LDV/SOF +RBV 12 weeks |
YES | 6 | after 2nd therapy: Not detected |
wrong regimens - initially diagnosed as G1b; |
|
| |||||||||
| 16 | 1B | 4 | LDV/SOF +RBV 12 weeks |
REL | LDV/SOF +RBV 24 weeks |
YES | 9 | Not done | retreatment with the same regimen - possible RAS to NS5A |
|
| |||||||||
| 22 | 1B | 4 | LDV/SOF +RBV 12 weeks |
NR | SOF+DCV +RBV 24 weeks |
NO | 14 | Not done | unknown non-response reason - possible RAS to NS5A |
|
| |||||||||
| 23 | 1B | 4 | ASV+DCV 24 weeks |
NR | OBV/PTV/r +DSV+RBV 12 weeks |
NO | 4 | Before 2nd therapy: NS3: S122R, D168E; NS5A: L31V, Y93H |
RAS to NS3 and NS5A |
GT: genotype; F: fibrosis; ETR: end of treatment; RAS: resistance associated substitution; NS3: nonstructural protein 3; NS5A: nonstructural protein 5A; NR: nonresponder; REL: relapse; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; SMV: simeprevir.